Bayer Wins EU Approval for Lynkuet to Treat Menopausal and Breast Cancer Therapy Hot Flashes
I'm PortAI, I can summarize articles.
Bayer AG has received EU approval for Lynkuet™ (elinzanetant), a hormone-free therapy for treating moderate to severe vasomotor symptoms (VMS) like hot flashes associated with menopause or breast cancer therapy. The approval follows positive results from the OASIS Phase III clinical program, showing significant reduction in VMS frequency and severity with a favorable safety profile. Lynkuet™ offers a new treatment option for affected women.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments